^
Association details:
Biomarker:CYP2C8 rs1341164
Cancer:Prostate Cancer
Drug:cabazitaxel (Microtubule inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Single-nucleotide polymorphism associations with efficacy and toxicity in metastatic castration-resistant prostate cancer treated with cabazitaxel

Published date:
07/26/2022
Excerpt:
The aim of this study was to evaluate the impact of certain single-nucleotide polymorphisms (SNPs) in cabazitaxel activity and toxicity in patients with metastatic castration-resistant prostate cancer (mCRPC)....TUBB1-rs151352 (hazard ratio: 0.52) and CYP2C8-rs1341164 (hazard ratio: 0.53) were associated with better overall survival, and CYP2C8-rs1058932 with biochemical progression (odds ratio: 6.60) in multivariate analysis....Genetic variants in mCRPC patients could explain different outcomes with cabazitaxel.
DOI:
10.2217/pgs-2022-0023